Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG13909 in Adults With Cushing's Disease
NCT06471829Phase 2Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of Lu AG13909 in Cushing's disease (CD), sponsored by Lundbeck. Primary endpoint: Urinary Free Cortisol Complete Response up to 490 days. Started Jun 2024; status: active, not recruiting.
02
Drugs
Lu AG13909
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT06471829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471829.